MA41381A - Composés participant à une liaison coopérative et leurs utilisations - Google Patents

Composés participant à une liaison coopérative et leurs utilisations

Info

Publication number
MA41381A
MA41381A MA041381A MA41381A MA41381A MA 41381 A MA41381 A MA 41381A MA 041381 A MA041381 A MA 041381A MA 41381 A MA41381 A MA 41381A MA 41381 A MA41381 A MA 41381A
Authority
MA
Morocco
Prior art keywords
liaison
cooperative
compounds participating
participating
compounds
Prior art date
Application number
MA041381A
Other languages
English (en)
French (fr)
Inventor
Neville John Anthony
Brian Roger Bowman
Matthew James Nichols
Mathew Edward Sowa
Dylan Talbot Stiles
Sharon Ann Townson
Gregory Lawrence Verdine
Original Assignee
Warp Drive Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warp Drive Bio Inc filed Critical Warp Drive Bio Inc
Publication of MA41381A publication Critical patent/MA41381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041381A 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations MA41381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101925P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
MA41381A true MA41381A (fr) 2017-11-28

Family

ID=56356469

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041381A MA41381A (fr) 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations

Country Status (7)

Country Link
US (4) US10039839B2 (https=)
EP (3) EP4545521A3 (https=)
JP (5) JP2018507251A (https=)
AR (1) AR105755A1 (https=)
MA (1) MA41381A (https=)
TW (1) TW201629069A (https=)
WO (1) WO2016112279A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
EP3247378B8 (en) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP4242304A3 (en) 2015-10-01 2024-02-07 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces
CN109641062A (zh) 2016-04-12 2019-04-16 华普卓威生物公司 用于产生化合物的组合物和方法
CA3058953A1 (en) * 2017-04-05 2018-10-11 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
IL269779B2 (en) * 2017-04-05 2026-04-01 Revolution Medicines Inc Methods and reagents for the analysis of protein-protein interfaces
WO2018195134A1 (en) * 2017-04-18 2018-10-25 X-Chem, Inc. Methods for identifying compounds
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN116083290B (zh) * 2022-11-21 2024-06-14 陕西省微生物研究所 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138807T1 (de) 1992-03-27 1996-06-15 American Home Prod 29-demethoxyrapamycin zur induktion der immunosuppression
CA2171629A1 (en) 1993-09-20 1995-03-30 Chaitan Khosla Recombinant production of novel polyketides
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
GB9410142D0 (en) 1994-05-20 1994-07-06 Univ Warwick Carbapenems
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6902913B2 (en) 1997-04-30 2005-06-07 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
AU4093799A (en) * 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
GB9927191D0 (en) 1999-11-17 2000-01-12 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20070203168A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
CN102224242B (zh) 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US8664186B2 (en) 2009-07-24 2014-03-04 Universite De Lorraine Stambomycin and derivatives, their production and their uses as drugs
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
WO2011049157A1 (ja) 2009-10-22 2011-04-28 ペプチドリーム株式会社 ペプチド翻訳合成におけるrapidディスプレイ法
US9250237B2 (en) 2010-11-30 2016-02-02 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2012174489A2 (en) * 2011-06-15 2012-12-20 The Ohio State University Small molecule composite surfaces as inhibitors of protein-protein interactions
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
WO2015132784A1 (en) 2014-03-03 2015-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
BR112021012057A2 (pt) * 2018-12-21 2021-10-19 Revolution Medicines, Inc. Compostos que participam de ligação cooperativa e usos dos mesmos

Also Published As

Publication number Publication date
US20250121077A1 (en) 2025-04-17
WO2016112279A8 (en) 2016-09-29
JP2022093718A (ja) 2022-06-23
JP2024149655A (ja) 2024-10-18
EP3757109A1 (en) 2020-12-30
AR105755A1 (es) 2017-11-08
EP3247377A4 (en) 2018-06-13
EP4545521A3 (en) 2025-08-06
WO2016112279A1 (en) 2016-07-14
US20220143202A1 (en) 2022-05-12
EP3247377A1 (en) 2017-11-29
JP2018507251A (ja) 2018-03-15
JP2020063256A (ja) 2020-04-23
TW201629069A (zh) 2016-08-16
US20160199506A1 (en) 2016-07-14
US10039839B2 (en) 2018-08-07
JP2026015411A (ja) 2026-01-29
US20180318434A1 (en) 2018-11-08
EP4545521A2 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
MA41381A (fr) Composés participant à une liaison coopérative et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3897644A4 (en) CONNECTIONS INVOLVING IN A COOPERATIVE BINDING AND USES THEREOF
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3649142A4 (en) JOINTS WITH SPLITABLE LINKER AND USES THEREOF
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3529279A4 (en) CD133 BINDERS AND USE THEREOF
MA50618A (fr) Polyrhérapies et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
EP3352776A4 (en) Htt repressors and uses thereof
EP3328199A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
EP3325488A4 (en) CHIRAL DIARYLMA CROCYCLES AND USES THEREOF
EP3397757A4 (en) Novel CRISPR-ASSOCIATED TRANSPOSASES AND USES THEREOF
EP3370528A4 (en) PROBIOTIC COMPOSITIONS AND USES THEREOF
MA52365A (fr) Composés et leurs utilisations
EP3768269A4 (en) CONNECTIONS AND USES THEREOF
EP3364958A4 (en) MODULATORS OF SESTRINE-GATOR2 INTERACTION AND USES THEREOF
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3347021A4 (en) CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MA45857A (fr) Composés et compositions, et utilisations associées
EP3399978A4 (en) Antiproliferative Compounds and their Pharmaceutical Compositions and Uses
EP3347020A4 (en) ACETAMIDE-THIENOTRIAZOLDIAZEPINE AND USES THEREOF